Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase

Chemistry and Biology

Volumn 10, Issue 3, 2003, Pages 225-231

  Hausch, Felix ^a,d   Halttunen, Tuula ^c   Mäki, Markku ^c   Khosla, Chaitan ^a,b  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY   (United States)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d ESBATech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0037352689     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(03)00045-0     Document Type: Article

References (36)

1. Maki M., Collin P. Coeliac disease. Lancet. 349:1997;1755-1759.
2. Sollid L.M. Molecular basis of celiac disease. Annu. Rev. Immunol. 18:2000;53-81.
3. Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology. 119:2000;234-242.
4. Arentz-Hansen H., Korner R., Molberg O., Quarsten H., Vader W., Kooy Y.M., Lundin K.E., Koning F., Roepstorff P., Sollid L.M.et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J. Exp. Med. 191:2000;603-612.
5. Anderson R.P., Degano P., Godkin A.J., Jewell D.P., Hill A.V. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat. Med. 6:2000;337-342.
6. Vader L.W., de Ru A., van der Wal Y., Kooy Y.M., Benckhuijsen W., Mearin M.L., Drijfhout J.W., van Veelen P., Koning F. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J. Exp. Med. 195:2002;643-649.
7. Shan L., Molberg O., Parrot I., Hausch F., Filiz F., Gray G.M., Sollid L.M., Khosla C. Structural basis for gluten intolerance in celiac sprue. Science. 297:2002;2275-2279.
8. Dieterich W., Ehnis T., Bauer M., Donner P., Volta U., Riecken E.O., Schuppan D. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3:1997;797-801.
9. Sollid L.M. Coeliac disease. dissecting a complex inflammatory disorder Nature Rev. Immunol. 2:2002;647-655.
10. Mearin M.L., Koning F. Tissue transglutaminase. master regulator of celiac sprue? J. Pediatr. Gastroenterol. Nutr. 36:2003;9-11.
11. De Laurenzi V., Melino G. Gene disruption of tissue transglutaminase. Mol. Cell. Biol. 21:2001;148-155.
12. Nanda N., Iismaa S.E., Owens W.A., Husain A., Mackay F., Graham R.M. Targeted inactivation of Gh/tissue transglutaminase II. J. Biol. Chem. 276:2001;20673-20678.
13. Piper J.L., Gray G.M., Khosla C. High selectivity of human tissue transglutaminase for immunoactive gliadin peptides. implications for celiac sprue Biochemistry. 41:2002;386-393.
14. Fleckenstein B., Molberg O., Qiao S.W., Schmid D.G., Von Der Mulbe F., Elgstoen K., Jung G., Sollid L.M. Gliadin T cell epitope selection by tissue transglutaminase in Celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation reactions. J. Biol. Chem. 277:2002;34109-34116.
15. Aeschlimann D., Thomazy V. Protein crosslinking in assembly and remodelling of extracellular matrices. the role of transglutaminases Connect. Tissue Res. 41:2000;1-27.
16. Kim S.Y., Jeitner T.M., Steinert P.M. Transglutaminases in disease. Neurochem. Int. 40:2002;85-103.
17. Folk J.E. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation. Adv. Enzymol. Relat. Areas Mol. Biol. 54:1983;1-56.
18. Lorand L., Conrad S.M. Transglutaminases. Mol. Cell. Biochem. 58:1984;9-35.
19. Marrano C., de Macedo P., Keillor J.W. Evaluation of novel dipeptide-bound alpha,beta-unsaturated amides and epoxides as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg. Med. Chem. 9:2001;1923-1928.
20. Marrano C., de Macedo P., Gagnon P., Lapierre D., Gravel C., Keillor J.W. Synthesis and evaluation of novel dipeptide-bound 1,2,4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg. Med. Chem. 9:2001;3231-3241.
21. de Macedo P., Marrano C., Keillor J.W. Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg. Med. Chem. 10:2002;355-360.
22. Parrot I., Huang P.C., Khosla C. Circular dichroism and nuclear magnetic resonance spectroscopic analysis of immunogenic gluten peptides and their analogs. J. Biol. Chem. in press:2002.
23. Hausch F., Shan L., Santiago N.A., Gray G.M., Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am. J. Physiol. Gastrointest. Liver Physiol. 283:2002;G996-G1003.
24. Freund K.F., Doshi K.P., Gaul S.L., Claremon D.A., Remy D.C., Baldwin J.J., Pitzenberger S.M., Stern A.M. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives. mechanism of factor XIIIa inactivation Biochemistry. 33:1994;10109-10119.
25. Tate S.S., Meister A. Gamma-glutamyl transpeptidase from kidney. Methods Enzymol. 113:1985;400-419.
26. Shaw E. Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases. Methods Enzymol. 244:1994;649-656.
27. Chittur S.V., Klem T.J., Shafer C.M., Davisson V.J. Mechanism for acivicin inactivation of triad glutamine amidotransferases. Biochemistry. 40:2001;876-887.
28. Day N., Keillor J.W. A continuous spectrophotometric linked enzyme assay for transglutaminase activity. Anal. Biochem. 274:1999;141-144.
29. Scholtz, J.M., Bartlett, P.A. (1989) A convenient differential protection strategy for functional group manipulation of aspartic and glutamic acids. Synthesis 542-544.
30. Cook N.D., Upperton K.P., Challis B.C., Peters T.J. The donor specificity and kinetics of the hydrolysis reaction of gamma-glutamyltransferase. Biochim. Biophys. Acta. 914:1987;240-245.
31. Castonguay R., Lherbet C., Keillor J.W. Mapping the active site of rat kidney gamma-glutamyl transpeptidase using activated esters and their amide derivatives. Bioorg. Med. Chem. 10:2002;4185-4191.
32. Halttunen T., Marttinen A., Rantala I., Kainulainen H., Maki M. Fibroblasts and transforming growth factor beta induce organization and differentiation of T84 human epithelial cells. Gastroenterology. 111:1996;1252-1262.
33. Halttunen T., Maki M. Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterology. 116:1999;566-572.
34. Molberg O., McAdam S., Lundin K.E., Kristiansen C., Arentz-Hansen H., Kett K., Sollid L.M. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur. J. Immunol. 31:2001;1317-1323.
35. Achyuthan K.E., Slaughter T.F., Santiago M.A., Enghild J.J., Greenberg C.S. Factor XIIIa-derived peptides inhibit transglutaminase activity. Localization of substrate recognition sites. J. Biol. Chem. 268:1993;21284-21292.
36. Kuhn, N., and Kratz, T. (1993) Synthesis of imidazol-2-ylidenes by reduction of imidazol-2(3H)-thiones. Synthesis 561-562.